ABOS Acumen Pharmaceuticals, Inc.Stock Price & Overview
$2.690.04 (+1.51%)3:59 PM 12/04/23
NASDAQ | $USD | Post-Market: $2.72 +0.03 (+1.12%) 7:05 PM
People Also Follow
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.